Oncimmune Share News (ONC)

Oncimmune Information

This share is currently suspended. It was suspended at a price of 1.2699

There is currently no data for ONC

REMOVE ADS

Oncimmune signs agreement with major cancer centre to profile patients

Fri, 23rd Jul 2021 12:46

(Alliance News) - Immunodiagnostics group Oncimmune Holdings PLC on Friday said it has signed an autoantibody profiling contract with Dana-Farber Cancer Institute.

Shares in Nottingham, England-based Oncimmune were up 5.6% to 179.50 pence each in London on Friday afternoon.

Dana-Farber is a clinical affiliate and research institute of Harvard Medical School and a cancer research organisation.

Under the agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTag, to identify autoantibodies that can be predictive of patient response or associated with resistance to checkpoint inhibitors and chemotherapy.

In addition, SeroTag will be used for identifying autoantibodies that can be predictive of immune-related adverse events in response to treatment.

The project is scheduled to complete by the end of 2021.

"SeroTag is a high-throughput, multiplex, discovery technology based on Oncimmune's in-house protein library, one of the largest in the world, with a unique, ever-growing repository of disease data for indications such as autoimmune and infectious diseases as well as cancer," the company said.

By Amrit Sahota; newsroom@alliancenews.com